• Alias: IMGN853; anti-FOLR1 monoclonal antibody-maytansinoid conjugate IMGN853
    • An immunoconjugate consisting of the humanized monoclonal antibody M9346A against FOLR1 conjugated, via the disulfide-containing cleavable linker sulfo- PDB, to the cytotoxic maytansinoid DM4. After antibody–antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and the growth of FOLR1-expressing tumor cells.
    • Phase 3 mirvetuximab versus standard of care in advanced, epithelial ovarian cancer, primary peritoneal cancer and/or fallopian tube cancer; phase 1 in FRa-expressing triple-negative breast cancer
    • Recommended phase 2 dose: 6 Dose is based on actual ideal body weight. May need to use prophylactic steroid eye drops to reduce ocular toxicities.
    Other topics in Targeted and Immunotherapy Agents